Ocular Therapeutix (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,885 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Sanjay Nayak sold 1,885 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $12.04, for a total value of $22,695.40. Following the transaction, the insider directly owned 279,738 shares of the company’s stock, valued at $3,368,045.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ocular Therapeutix Price Performance

OCUL stock opened at $12.32 on Thursday. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $12.91. The stock’s fifty day simple moving average is $11.13 and its 200-day simple moving average is $8.78. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -9.63 and a beta of 1.49.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The business had revenue of $13.46 million for the quarter, compared to analyst estimates of $13.12 million. During the same quarter last year, the business earned ($0.26) EPS. Ocular Therapeutix’s revenue for the quarter was down 17.7% compared to the same quarter last year. Equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Scotiabank decreased their price objective on Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating on the stock in a report on Wednesday, August 6th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a report on Thursday, May 29th. Finally, Needham & Company LLC raised their price objective on Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Ocular Therapeutix has an average rating of “Buy” and an average price target of $17.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Marex Group plc acquired a new position in shares of Ocular Therapeutix during the second quarter worth about $115,000. Hudson Bay Capital Management LP acquired a new position in shares of Ocular Therapeutix during the second quarter worth about $502,000. Second Line Capital LLC lifted its stake in shares of Ocular Therapeutix by 11.4% during the second quarter. Second Line Capital LLC now owns 385,467 shares of the biopharmaceutical company’s stock worth $3,577,000 after purchasing an additional 39,369 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of Ocular Therapeutix by 127.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 27,185 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 15,209 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Ocular Therapeutix by 883.9% during the second quarter. Tower Research Capital LLC TRC now owns 36,297 shares of the biopharmaceutical company’s stock worth $337,000 after purchasing an additional 32,608 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.